ustekinumab-话题@MedSci

#ustekinumab#

25篇内容 | 1836人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=2264400, encodeId=1f54226440003, content=<a href='/topic/show?id=fde528896bd' target=_blank style='color:#2F92EE;'>#克罗恩病#</a> <a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a> <a href='/topic/show?id=58ee1549925' target=_blank style='color:#2F92EE;'>#risankizumab#</a>, objectTitle=NEJM：Risankizumab与Ustekinumab治疗中重度克罗恩病疗效和安全性对比, objectType=article, longId=875438, objectId=d51a8e5438a6, topicUrl=null, isHasObj=0, objectCover=https://img.medsci.cn/20240704/1720065244146_92910.jpg, objectUrl=/article/show_article.do?id=d51a8e5438a6, replyNumber=0, likeNumber=14, createdTime=2025-05-10, rootId=0, userName=梅斯管理员, userId=cade5395722, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=上海, moduleDTOList=[ModuleDTO(moduleId=d51a8e5438a6, moduleTitle=NEJM：Risankizumab与Ustekinumab治疗中重度克罗恩病疗效和安全性对比, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=d51a8e5438a6)], followStatus=false, userIsMember=false, type=null, lengthMark=0), GetTopicListResponse(id=1642726, encodeId=c3831642e26e0, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较, objectType=article, longId=737625, objectId=1396e376252d, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1396e376252d, replyNumber=0, likeNumber=110, createdTime=2023-08-04, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1396e376252d, moduleTitle=J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1396e376252d)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642723, encodeId=e1251642e238f, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=Front Immunol：银屑病患者ustekinumab应答的全基因组关联研究, objectType=article, longId=299672, objectId=9b7d2996e2b8, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=9b7d2996e2b8, replyNumber=0, likeNumber=129, createdTime=2022-06-06, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=9b7d2996e2b8, moduleTitle=Front Immunol：银屑病患者ustekinumab应答的全基因组关联研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=9b7d2996e2b8)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642725, encodeId=401f1642e2530, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=JGH：乌司奴单抗(Ustekinumab)不会增加既往患有恶性肿瘤的炎症性肠病患者新发或复发癌症的风险, objectType=article, longId=729950, objectId=a49de299506f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=a49de299506f, replyNumber=0, likeNumber=102, createdTime=2023-03-16, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=a49de299506f, moduleTitle=JGH：乌司奴单抗(Ustekinumab)不会增加既往患有恶性肿瘤的炎症性肠病患者新发或复发癌症的风险, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=a49de299506f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642724, encodeId=ea671642e24f4, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=J Am Acad Dermatol：Ustekinumab治疗儿童斑块型银屑病的真实经验, objectType=article, longId=300165, objectId=0224300165af, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0224300165af, replyNumber=0, likeNumber=113, createdTime=2022-03-31, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0224300165af, moduleTitle=J Am Acad Dermatol：Ustekinumab治疗儿童斑块型银屑病的真实经验, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0224300165af)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642722, encodeId=c8ab1642e225c, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, objectType=article, longId=213917, objectId=365621391e66, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=365621391e66, replyNumber=0, likeNumber=136, createdTime=2021-11-18, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=365621391e66, moduleTitle=Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=365621391e66)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642720, encodeId=33fe1642e2063, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=IBD: Ustekinumab剂量强化后克罗恩病治疗仍然失败的预测因子, objectType=article, longId=203049, objectId=aa44203049c4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=aa44203049c4, replyNumber=0, likeNumber=135, createdTime=2021-10-18, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=aa44203049c4, moduleTitle=IBD: Ustekinumab剂量强化后克罗恩病治疗仍然失败的预测因子, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=aa44203049c4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642721, encodeId=95dd1642e21c9, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=JCC：乌司奴单抗（Ustekinumab）在溃疡性结肠炎中的有效性和安全性分析, objectType=article, longId=210176, objectId=e40e2101e64c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=e40e2101e64c, replyNumber=0, likeNumber=91, createdTime=2021-09-18, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=e40e2101e64c, moduleTitle=JCC：乌司奴单抗（Ustekinumab）在溃疡性结肠炎中的有效性和安全性分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=e40e2101e64c)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642719, encodeId=97b91642e1997, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, objectType=article, longId=198548, objectId=231019854869, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=231019854869, replyNumber=0, likeNumber=111, createdTime=2020-10-29, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=231019854869, moduleTitle=IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=231019854869)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642718, encodeId=02551642e1854, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, objectType=article, longId=195839, objectId=0f4c19583900, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0f4c19583900, replyNumber=0, likeNumber=79, createdTime=2021-05-23, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0f4c19583900, moduleTitle=AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0f4c19583900)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642717, encodeId=21f81642e1789, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, objectType=article, longId=193135, objectId=1689193135a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=1689193135a7, replyNumber=0, likeNumber=124, createdTime=2021-02-10, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=1689193135a7, moduleTitle=英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=1689193135a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642715, encodeId=940e1642e1555, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=NEJM：Ustekinumab用于中重度溃疡性结肠炎, objectType=article, longId=180115, objectId=7fca18011547, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=7fca18011547, replyNumber=0, likeNumber=160, createdTime=2020-07-07, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=7fca18011547, moduleTitle=NEJM：Ustekinumab用于中重度溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=7fca18011547)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642713, encodeId=b56b1642e13b0, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=Gastroenterology：Ustekinumab对CD患者组织学的影响, objectType=article, longId=175622, objectId=c8a51e562277, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c8a51e562277, replyNumber=0, likeNumber=90, createdTime=2020-06-23, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c8a51e562277, moduleTitle=Gastroenterology：Ustekinumab对CD患者组织学的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c8a51e562277)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642711, encodeId=6eeb1642e1143, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=JCC： Ustekinumab治疗难治性克罗恩病的儿科患者的疗效分析, objectType=article, longId=165629, objectId=0499165629e0, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=0499165629e0, replyNumber=0, likeNumber=90, createdTime=2019-09-30, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=0499165629e0, moduleTitle=JCC： Ustekinumab治疗难治性克罗恩病的儿科患者的疗效分析, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=0499165629e0)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642714, encodeId=b0691642e140f, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=CHMP建议批准Stelara（ustekinumab）治疗中重度活动性溃疡性结肠炎, objectType=article, longId=176378, objectId=18ff1e63783f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=18ff1e63783f, replyNumber=0, likeNumber=130, createdTime=2020-04-04, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=18ff1e63783f, moduleTitle=CHMP建议批准Stelara（ustekinumab）治疗中重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=18ff1e63783f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642716, encodeId=773c1642e1660, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, objectType=article, longId=181708, objectId=3487181e0866, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3487181e0866, replyNumber=0, likeNumber=90, createdTime=2020-09-20, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3487181e0866, moduleTitle=强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3487181e0866)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642710, encodeId=182a1642e1075, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=2019年美国皮肤病学（AAD）大会：Risankizumab在中重度银屑病中比Ustekinumab更有效, objectType=article, longId=162073, objectId=5eb21620e3e2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5eb21620e3e2, replyNumber=0, likeNumber=86, createdTime=2019-08-10, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5eb21620e3e2, moduleTitle=2019年美国皮肤病学（AAD）大会：Risankizumab在中重度银屑病中比Ustekinumab更有效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5eb21620e3e2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642712, encodeId=e3681642e123f, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=Dig Liver Dis： ustekinumab在伴有银屑病或银屑病关节炎的炎症性肠病患者中的实际效果, objectType=article, longId=175000, objectId=5c7b1e5000b6, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=5c7b1e5000b6, replyNumber=0, likeNumber=122, createdTime=2020-06-17, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=5c7b1e5000b6, moduleTitle=Dig Liver Dis： ustekinumab在伴有银屑病或银屑病关节炎的炎症性肠病患者中的实际效果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=5c7b1e5000b6)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642708, encodeId=21d11642e08d3, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=JCC：尤特科单抗（Ustekinumab）对中度至重度克罗恩病患者健康相关生活质量的影响, objectType=article, longId=147607, objectId=10c814e607e1, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=10c814e607e1, replyNumber=0, likeNumber=107, createdTime=2019-05-12, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=10c814e607e1, moduleTitle=JCC：尤特科单抗（Ustekinumab）对中度至重度克罗恩病患者健康相关生活质量的影响, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=10c814e607e1)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1642709, encodeId=54fd1642e0940, content=<a href='/topic/show?id=39071820109' target=_blank style='color:#2F92EE;'>#ustekinumab#</a>, objectTitle=Gastroenterology：Ustekinumab诱导克罗恩病患者炎症缓解的疗效, objectType=article, longId=151113, objectId=8fb4151113a7, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8fb4151113a7, replyNumber=0, likeNumber=102, createdTime=2019-03-13, rootId=0, userName=12498f1em15(暂无昵称), userId=2ae023003775, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8fb4151113a7, moduleTitle=Gastroenterology：Ustekinumab诱导克罗恩病患者炎症缓解的疗效, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8fb4151113a7)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

ustekinumab

2020-05-29

梅斯管理员 (审核中...)

前往app查看评论内容

#克罗恩病# #ustekinumab# #risankizumab#

NEJM：Risankizumab与Ustekinumab治疗中重度克罗恩病疗效和安全性对比

2025-05-10发表于上海

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

J Immunol Res：Risankizumab与Ustekinumab治疗银屑病疗效和安全性比较

2023-08-04

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

Front Immunol：银屑病患者ustekinumab应答的全基因组关联研究

2022-06-06

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

JGH：乌司奴单抗(Ustekinumab)不会增加既往患有恶性肿瘤的炎症性肠病患者新发或复发癌症的风险

2023-03-16

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

J Am Acad Dermatol：Ustekinumab治疗儿童斑块型银屑病的真实经验

2022-03-31

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

Alvotech启动Stelara® (Ustekinumab)拟议生物仿制药AVT04的临床研究

2021-11-18

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

IBD: Ustekinumab剂量强化后克罗恩病治疗仍然失败的预测因子

2021-10-18

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

JCC：乌司奴单抗（Ustekinumab）在溃疡性结肠炎中的有效性和安全性分析

2021-09-18

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

IL-12/IL-23单抗Stelara（ustekinumab），获得FDA批准治疗牛皮癣儿童患者

2020-10-29

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

AAD 2020：3期临床证实IL-17A/IL-17F单抗Bimekizumab治疗牛皮癣，优于IL-12/IL-23单抗ustekinumab

2021-05-23

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

英国NICE推荐将IL-12/IL-23单抗ustekinumab，用于治疗活动性中度至重度溃疡性结肠炎

2021-02-10

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

NEJM：Ustekinumab用于中重度溃疡性结肠炎

2020-07-07

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

Gastroenterology：Ustekinumab对CD患者组织学的影响

2020-06-23

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

JCC： Ustekinumab治疗难治性克罗恩病的儿科患者的疗效分析

2019-09-30

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

CHMP建议批准Stelara（ustekinumab）治疗中重度活动性溃疡性结肠炎

2020-04-04

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

强生宣布其IL-12/IL-23单抗STELARA（ustekinumab）喜获FDA批准治疗中度至重度活动性溃疡性结肠炎

2020-09-20

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

2019年美国皮肤病学（AAD）大会：Risankizumab在中重度银屑病中比Ustekinumab更有效

2019-08-10

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

Dig Liver Dis： ustekinumab在伴有银屑病或银屑病关节炎的炎症性肠病患者中的实际效果

2020-06-17

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

JCC：尤特科单抗（Ustekinumab）对中度至重度克罗恩病患者健康相关生活质量的影响

2019-05-12

12498f1em15(暂无昵称) (审核中...)

前往app查看评论内容

#ustekinumab#

Gastroenterology：Ustekinumab诱导克罗恩病患者炎症缓解的疗效

2019-03-13

科室
- - 订阅+
  - 更多科室
工具
服务